Reversible Splenial Lesion Syndrome (RESLES) After Chemotherapy of Oral Tegafur-uracil in a Female With Locally Rectal Adenocarcinoma
A 42-year-old woman with reversible splenial lesion syndrome (RESLES) and rectal adenocarcinoma presented with sudden-onset delirium after the sixth cycle of her chemotherapy drug, oral tegafur-uracil (300 mg/m/day, days 1-14, with treatment cycle repeated every 21 days). Accompanied by the anti-CV2 antibody, paraphasia, and a loss of bimanual coordination, the patient's etiology and clinical manifestations of RESLES are unlike those of other reported cases of RESLES. Tegafur-uracil is an oral fluoropyrimidine that has a similar effect to 5-fluorouracil as an adjuvant treatment for colorectal cancer. The possibility that the toxicity of chemotherapeutic drugs may play a role in the pathogenesis of cytotoxic edema in the splenium of the corpus callosum and extracallosal white matter should be investigated further.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology - 33(2020), 4 vom: 01. Dez., Seite 283-287 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ge, Yu-Xing [VerfasserIn] |
---|
Links: |
---|
Themen: |
1548R74NSZ |
---|
Anmerkungen: |
Date Completed 19.02.2021 Date Revised 19.02.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/WNN.0000000000000250 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM318303698 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM318303698 | ||
003 | DE-627 | ||
005 | 20231225165054.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/WNN.0000000000000250 |2 doi | |
028 | 5 | 2 | |a pubmed24n1060.xml |
035 | |a (DE-627)NLM318303698 | ||
035 | |a (NLM)33264157 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ge, Yu-Xing |e verfasserin |4 aut | |
245 | 1 | 0 | |a Reversible Splenial Lesion Syndrome (RESLES) After Chemotherapy of Oral Tegafur-uracil in a Female With Locally Rectal Adenocarcinoma |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.02.2021 | ||
500 | |a Date Revised 19.02.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a A 42-year-old woman with reversible splenial lesion syndrome (RESLES) and rectal adenocarcinoma presented with sudden-onset delirium after the sixth cycle of her chemotherapy drug, oral tegafur-uracil (300 mg/m/day, days 1-14, with treatment cycle repeated every 21 days). Accompanied by the anti-CV2 antibody, paraphasia, and a loss of bimanual coordination, the patient's etiology and clinical manifestations of RESLES are unlike those of other reported cases of RESLES. Tegafur-uracil is an oral fluoropyrimidine that has a similar effect to 5-fluorouracil as an adjuvant treatment for colorectal cancer. The possibility that the toxicity of chemotherapeutic drugs may play a role in the pathogenesis of cytotoxic edema in the splenium of the corpus callosum and extracallosal white matter should be investigated further | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antimetabolites, Antineoplastic |2 NLM | |
650 | 7 | |a Tegafur |2 NLM | |
650 | 7 | |a 1548R74NSZ |2 NLM | |
700 | 1 | |a Lin, Ying-Ying |e verfasserin |4 aut | |
700 | 1 | |a Bi, Qian-Qian |e verfasserin |4 aut | |
700 | 1 | |a Chen, Yu-Juan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology |d 2003 |g 33(2020), 4 vom: 01. Dez., Seite 283-287 |w (DE-627)NLM125638558 |x 1543-3641 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2020 |g number:4 |g day:01 |g month:12 |g pages:283-287 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/WNN.0000000000000250 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 33 |j 2020 |e 4 |b 01 |c 12 |h 283-287 |